Table 4 Factors associated with overall survival in univariate and multivariate analysis (n = 85).

From: Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy

Variable

HR univariable (95% CI)

p value

HR multivariable (95% CI)

p value

Older age >70 year (vs ≤70 year)

1.07 (0.64–1.80)

0.799

0.98 (0.95–1.01)

0.112

Male sex (vs female)

1.37 (0.82–2.29)

0.224

ECOG PS 1 (vs 0)

1.11 (0.62–1.97)

0.728

1.09 (0.59–1.99)

0.786

ECOG PS 2 (vs 0)

6.33 (2.04–19.66)

0.001

6.98 (2.07–23.54)

0.002

Normal BMI (vs low)

0.90 (0.44–1.85)

0.774

Serum albumin level

0.93 (0.84–1.03)

0.145

Total muscle area

1.00 (0.99–1.01)

0.455

Skeletal muscle index

0.97 (0.94–1.01)

0.126

Psoas muscle density

1.00 (0.97–1.04)

0.964

Total psoas index

0.85 (0.70–1.04)

0.111

Indexed psoas density

1.02 (0.50–2.08)

0.960

Low muscle mass (vs normal)a

3.63 (1.29–10.25)

0.015

4.41 (1.50–12.94)

0.007

Myosteatosis (vs absence)b

1.22 (0.67–2.22)

0.513

0.73 (0.35–1.53)

0.408

  1. BMI body mass index, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio.
  2. aLow muscle mass was defined as SMI < 38.5 cm²/m² for women and <52.4 cm²/m² for men.
  3. bMyosteatosis was defined as mean PMD < 41 HU if BMI < 25 and <33 HU if BMI > 25.
  4. Bold data show statistically significant results.